TNNI3 and coronary artery disorder: The current study assessed whether coronary 18F-fluoride activity identifies patients with stable multivessel coronary artery disease who respond favorably to ticagrelor as assessed by a reduction in high-sensitivity cardiac troponin I concentrations.